The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Mechanisms and regulation of endothelial VEGF receptor signalling
Simons, M., Gordon, E., & Claesson-Welsh, L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.87 · Cited by 1,498
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Barleon, B., Sozzani, S., Zhou, D., Weich, H., Mantovani, A., & Marme, D. (1996) · Blood · doi:10.1182/blood.v87.8.3336.bloodjournal8783336 · Cited by 1,356
Bussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., & Comoglio, P. M. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.629 · Cited by 1,337
Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,333
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
The Role of Mechanical Forces in Tumor Growth and Therapy
Jain, R. K., Martin, J. D., & Stylianopoulos, T. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105259 · Cited by 1,044
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Fiedler, U., Reiss, Y., Scharpfenecker, M., Grunow, V., Koidl, S., Thurston, G., Gale, N. W., Witzenrath, M., Rosseau, S., Suttorp, N., et al. (2006) · Nature Medicine · doi:10.1038/nm1351 · Cited by 933
Kuang, D.-M., Zhao, Q., Peng, C., Xu, J., Zhang, J.-P., Wu, C., & Zheng, L. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 903
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Cellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Serafini, P., Mgebroff, S., Noonan, K., & Borrello, I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6621 · Cited by 673
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582
Endothelial proliferation in tumours and normal tissues: Continuous labelling studies
Hobson, B., & Denekamp, J. (1984) · British Journal of Cancer · doi:10.1038/bjc.1984.66 · Cited by 565
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H.-J., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 564
Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O'Brien-Jenkins, A., Gimotty, P. A., & Coukos, G. (2008) · Nature Medicine · doi:10.1038/nm1699 · Cited by 546
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 538
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Azuma, T., Yao, S., Zhu, G., Flies, A. S., Flies, S. J., & Chen, L. (2008) · Blood · doi:10.1182/blood-2007-11-123141 · Cited by 531
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. D., Carbone, D. P., & Gabrilovich, D. I. (1998) · PubMed · Cited by 530
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X., & Delgoffe, G. M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0103 · Cited by 520
Martinet, L., Garrido, I., Filleron, T., Le Guellec, S., Bellard, E., Fournie, J.-J., Rochaix, P., & Girard, J.-P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0431 · Cited by 516
Qin, Z., & Blankenstein, T. (2000) · Immunity · doi:10.1016/s1074-7613(00)80218-6 · Cited by 511
Venneri, M. A., Palma, M. D., Ponzoni, M., Pucci, F., Scielzo, C., Zonari, E., Mazzieri, R., Doglioni, C., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2006-10-053504 · Cited by 505
Xin, H., Zhang, C., Herrmann, A., Du, Y., Figlin, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4323 · Cited by 504
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis
Rodig, N., Ryan, T., Allen, J. A., Pang, H., Grabie, N., Chernova, T., Greenfield, E. A., Liang, S. C., Sharpe, A. H., Lichtman, A. H., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324270 · Cited by 492
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., & Gabrilovich, D. I. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1224 · Cited by 481
Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E., & Carbone, D. P. (1999) · PubMed · Cited by 459
Melder, R. J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L., & Jain, R. K. (1996) · Nature Medicine · doi:10.1038/nm0996-992 · Cited by 451
The PDL1-PD1 Axis Converts Human T H 1 Cells into Regulatory T Cells
Amarnath, S., Mangus, C. W., Wang, J. C. M., Wei, F., He, A., Kapoor, V., Foley, J. E., Massey, P. R., Felizardo, T. C., Riley, J. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003130 · Cited by 446
Genes that Distinguish Physiological and Pathological Angiogenesis
Seaman, S., Stevens, J., Yang, M. Y., Logsdon, D., Graff-Cherry, C., & St. Croix, B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.017 · Cited by 419
Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers
Dieu‐Nosjean, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Sautès‐Fridman, C. (2016) · Immunological Reviews · doi:10.1111/imr.12405 · Cited by 417
Scharpfenecker, M., Fiedler, U., Reiss, Y., & Augustin, H. G. (2005) · Journal of Cell Science · doi:10.1242/jcs.01653 · Cited by 382
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Coffelt, S. B., Tal, A. O., Scholz, A., De Palma, M., Patel, S., Urbich, C., Biswas, S. K., Murdoch, C., Plate, K. H., Reiss, Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0012 · Cited by 343
Johansson-Percival, A., He, B., Li, Z.-J., Kjellén, A., Russell, K., Li, J., Larma, I., & Ganss, R. (2017) · Nature Immunology · doi:10.1038/ni.3836 · Cited by 331
Park, J.-S., Kim, I.-K., Han, S., Park, I., Kim, C., Bae, J., Oh, S. J., Lee, S., Kim, J. H., Woo, D.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.018 · Cited by 327
B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis
Mazanet, M. M., & Hughes, C. C. W. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3581 · Cited by 326
Dirkx, A. E. M., Egbrink, M. G. A. O., Kuijpers, M. J. E., van der Niet, S. T., Heijnen, V. V. T., Steege, J. C. A. B.-T., Wagstaff, J., & Griffioen, A. W. (2003) · PubMed · Cited by 325
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A. E., Hu-Lowe, D. D., & Christensen, J. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0489 · Cited by 319
Peterson, T. E., Kirkpatrick, N. D., Huang, Y., Farrar, C. T., Marijt, K. A., Kloepper, J., Datta, M., Amoozgar, Z., Seano, G., Jung, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525349113 · Cited by 317
Masiero, M., Simões, F. C., Han, H. D., Snell, C., Peterkin, T., Bridges, E., Mangala, L. S., Wu, S. Y.-Y., Pradeep, S., Li, D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.004 · Cited by 313
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0441-x · Cited by 311
Griffioen, A. W., Damen, C. A., Martinotti, S., Blijham, G. H., & Groenewegen, G. (1996) · PubMed · Cited by 282
Yasuda, S., Sho, M., Yamato, I., Yoshiji, H., Wakatsuki, K., Nishiwada, S., Yagita, H., & Nakajima, Y. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12069 · Cited by 276
Kusmartsev, S., Eruslanov, E., Kübler, H., Tseng, T., Sakai, Y., Su, Z., Kaliberov, S., Heiser, A., Rosser, C., Dahm, P., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.346 · Cited by 276
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells
Eppihimer, M., Gunn, J., Freeman, G., Greenfield, E., Chernova, T., Erickson, J., & Leonard, J. (2002) · Microcirculation · doi:10.1080/713774061 · Cited by 272
Dirkx, A. E. M., Egbrink, M. G. A. O., Castermans, K., van der Schaft, D. W. J., Thijssen, V. L. J. L., Dings, R. P. M., Kwee, L., Mayo, K. H., Wagstaff, J., Steege, J. C. A. B., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-4493com · Cited by 270
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
Kammertoens, T., Friese, C., Arina, A., Idel, C., Briesemeister, D., Rothe, M., Ivanov, A., Szymborska, A., Patone, G., Kunz, S., et al. (2017) · Nature · doi:10.1038/nature22311 · Cited by 269
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., Albert, J., Sparwasser, T., Sakaguchi, S., Westendorf, A. M., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111497 · Cited by 250
Dikov, M. M., Ohm, J. E., Ray, N., Tchekneva, E. E., Burlison, J., Moghanaki, D., Nadaf, S., & Carbone, D. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.215 · Cited by 244
Okunishi, K., Dohi, M., Nakagome, K., Tanaka, R., Mizuno, S., Matsumoto, K., Miyazaki, J.-I., Nakamura, T., & Yamamoto, K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4745 · Cited by 240
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
Qin, Z., Schwartzkopff, J., Pradera, F., Kammertoens, T., Seliger, B., Pircher, H., & Blankenstein, T. J. F. (2003) · PubMed · Cited by 235
Huang, Y., Chen, X., Dikov, M. M., Novitskiy, S. V., Mosse, C. A., Yang, L., & Carbone, D. P. (2007) · Blood · doi:10.1182/blood-2007-01-065714 · Cited by 230
Falcón, B. L., Hashizume, H., Koumoutsakos, P., Chou, J., Bready, J. V., Coxon, A., Oliner, J. D., & McDonald, D. M. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090391 · Cited by 224
New Members of the Platelet-Derived Growth Factor Family of Mitogens
Heldin, C.-H., Eriksson, U., & Östman, A. (2002) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2707 · Cited by 221
Coffelt, S. B., Chen, Y.-Y., Muthana, M., Welford, A. F., Tal, A. O., Scholz, A., Plate, K. H., Reiss, Y., Murdoch, C., De Palma, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002802 · Cited by 220
Rini, B. I., Stenzl, A., Zdrojowy, R., Kogan, M., Shkolnik, M., Oudard, S., Weikert, S., Bracarda, S., Crabb, S. J., Bedke, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30408-9 · Cited by 220
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer
Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1591 · Cited by 214
Alfaro, C., Suarez, N., Gonzalez, A., Solano, S., Erro, L., Dubrot, J., Palazon, A., Hervas-Stubbs, S., Gurpide, A., Lopez-Picazo, J. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604965 · Cited by 214
Adotevi, O., Pere, H., Ravel, P., Haicheur, N., Badoual, C., Merillon, N., Medioni, J., Peyrard, S., Roncelin, S., Verkarre, V., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f4c208 · Cited by 213
Manning, E. A., Ullman, J. G. M., Leatherman, J. M., Asquith, J. M., Hansen, T. R., Armstrong, T. D., Hicklin, D. J., Jaffee, E. M., & Emens, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0374 · Cited by 205
Benkhoucha, M., Santiago-Raber, M.-L., Schneiter, G., Chofflon, M., Funakoshi, H., Nakamura, T., & Lalive, P. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912437107 · Cited by 205
Liu, X.-D., Hoang, A., Zhou, L., Kalra, S., Yetil, A., Sun, M., Ding, Z., Zhang, X., Bai, S., German, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0244 · Cited by 204
Bouzin, C., Brouet, A., De Vriese, J., DeWever, J., & Feron, O. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1505 · Cited by 200
di Tomaso, E., Snuderl, M., Kamoun, W. S., Duda, D. G., Auluck, P. K., Fazlollahi, L., Andronesi, O. C., Frosch, M. P., Wen, P. Y., Plotkin, S. R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2602 · Cited by 199
Suppression, subversion and escape: the role of regulatory T cells in cancer progression
Oleinika, K., Nibbs, R. J., Graham, G. J., & Fraser, A. R. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2012.04657.x · Cited by 198
Kwilas, A. R., Ardiani, A., Donahue, R. N., Aftab, D. T., & Hodge, J. W. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0294-y · Cited by 192
Fricke, I., Mirza, N., Dupont, J., Lockhart, C., Jackson, A., Lee, J.-H., Sosman, J. A., & Gabrilovich, D. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0409 · Cited by 182
Huang, H., Langenkamp, E., Georganaki, M., Loskog, A., Fuchs, P. F., Dieterich, L. C., Kreuger, J., & Dimberg, A. (2015) · The FASEB Journal · doi:10.1096/fj.14-250985 · Cited by 182
Black, M., Barsoum, I. B., Truesdell, P., Cotechini, T., Macdonald-Goodfellow, S. K., Petroff, M., Siemens, D. R., Koti, M., Craig, A. W. B., & Graham, C. H. (2016) · Oncotarget · doi:10.18632/oncotarget.7235 · Cited by 182
Nasarre, P., Thomas, M., Kruse, K., Helfrich, I., Wolter, V., Deppermann, C., Schadendorf, D., Thurston, G., Fiedler, U., & Augustin, H. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3030 · Cited by 181
Shetty, S., Weston, C. J., Oo, Y. H., Westerlund, N., Stamataki, Z., Youster, J., Hubscher, S. G., Salmi, M., Jalkanen, S., Lalor, P. F., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002961 · Cited by 173
和田, 純., Suzuki, H. Y., Fuchino, R., Yamasaki, A., Nagai, S., Yanai, K., Koga, K., Nakamura, M., Tanaka, M., Morisaki, T., et al. (2009) · PubMed · Cited by 169
Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bähr, O., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505505 · Cited by 169
Gavalas, N. G., Tsiatas, M., Tsitsilonis, O., Politi, E., Ioannou, K., Ziogas, A. C., Rodolakis, A., Vlahos, G., Thomakos, N., Haidopoulos, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.468 · Cited by 167
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0206 · Cited by 164
Balan, M., y Teran, E. M., Waaga-Gasser, A. M., Gasser, M., Choueiri, T. K., Freeman, G. J., & Pal, S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612689 · Cited by 161
Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation
Dieterich, L. C., Ikenberg, K., Cetintas, T., Kapaklikaya, K., Hutmacher, C., & Detmar, M. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00066 · Cited by 160
Huo, M., Zhao, Y., Satterlee, A., Wang, Y., Xu, Y., & Huang, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.013 · Cited by 159
Huang, X., Bai, X., Cao, Y., Wu, J., Huang, M., Tang, D., Tao, S., Zhu, T., Liu, Y., Yang, Y., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090397 · Cited by 156
Rini, B. I., Stein, M. N., Shannon, P., Eddy, S., Tyler, A. J., Stephenson, J., Catlett, L., Huang, B., Healey, D. I., & Gordon, M. S. (2010) · Cancer · doi:10.1002/cncr.25639 · Cited by 155
Enhancement of T cell recruitment and infiltration into tumours
Oelkrug, C., & Ramage, J. M. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12382 · Cited by 153
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.
Eppihimer, M. J., Gunn, J., Freeman, G. J., Greenfield, E. A., Chernova, T., Erickson, J., & Leonard, J. P. (2002) · PubMed · doi:10.1038/sj/mn/7800123 · Cited by 149
Bose, A., Taylor, J. L., Alber, S. M., Watkins, S. C., García, J. A., Rini, B. I., Ko, J. S., Cohen, P. A., Finke, J. H., & Storkus, W. J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25863 · Cited by 145
Yuan, J. D., Zhou, J. M., Dong, Z., Tandon, S., Kuk, D., Panageas, K. S., Wong, P., Wu, X., Naidoo, J., Page, D. B., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0163 · Cited by 142
Huang, H., Lai, J.-Y., Do, J., Liu, D., Li, L., Rosario, J. D., Doppalapudi, V. R., Pirie-Shepherd, S. R., Levin, N., Bradshaw, C. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2317 · Cited by 142
Srivastava, K., Hu, J., Korn, C., Savant, S., Teichert, M., Kapel, S. S., Jugold, M., Besemfelder, E., Thomas, M., Pasparakis, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.005 · Cited by 140
Mimura, K., Kono, K., Takahashi, A., Kawaguchi, Y., & Fujii, H. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0234-7 · Cited by 138
Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
Arjaans, M., Munnink, T. H. O., Oosting, S. F., van Scheltinga, A. G. T. T., Gietema, J. A., Garbacik, E. T., Timmer‐Bosscha, H., Hooge, M. N. L., Schroder, C. P., & de Vries, E. G. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3518 · Cited by 125
Anti-angiogenesis: making the tumor vulnerable to the immune system
Griffioen, A. W. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0524-3 · Cited by 114
Komarowska, I., Coe, D., Wang, G., Haas, R., Mauro, C., Kishore, M., Cooper, D., Nadkarni, S., Fu, H., Steinbrüchel, D. A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.014 · Cited by 105
Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis
Karikoski, M., Marttila‐Ichihara, F., Elima, K., Rantakari, P., Hollmén, M., Kelkka, T., Gerke, H., Huovinen, V., Irjala, H., Holmdahl, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1236 · Cited by 104
Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin–dependent manner
Scholz, A., Lang, V., Henschler, R., Czabanka, M., Vajkoczy, P., Chavakis, E., Drynski, J., Harter, P. N., Mittelbronn, M., Dumont, D. J., et al. (2011) · Blood · doi:10.1182/blood-2011-03-343293 · Cited by 102
Lissoni, P., Malugani, F., Bonfanti, A., Bucovec, R., Secondino, S., Brivio, F., Bravo, A. F., Ferrante, R., Vigoré, L., Rovelli, F., et al. (2001) · PubMed · Cited by 102
The role of immunosuppression of mesenchymal stem cells in tissue repair and tumor growth
Han, Z., Jing, Y., Zhang, S., Liu, Y., Shi, Y., & Wei, L. (2012) · Cell & Bioscience · doi:10.1186/2045-3701-2-8 · Cited by 101
Boissel, N., Rousselot, P. H., Raffoux, E., Cayuela, J., Maarek, O., Charron, D. J., Degos, L., Dombret, H., Toubert, A., & Réa, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403474 · Cited by 97
Ilangumaran, S., Villalobos-Hernandez, A., Bobbala, D., & Ramanathan, S. (2016) · Cytokine · doi:10.1016/j.cyto.2015.12.013 · Cited by 96
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
Ishibashi, M., Tamura, H., Sunakawa, M., Kondo, A., Okuyama, N., Hamada, Y., Moriya, K., Choi, I., Tamada, K., & Inokuchi, K. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0296 · Cited by 96
Wu, X., Giobbie‐Hurder, A., Liao, X., Lawrence, D. P., McDermott, D. F., Zhou, J. M., Rodig, S. J., & Hodi, F. S. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0084 · Cited by 94
The HGF Receptor/Met Tyrosine Kinase Is a Key Regulator of Dendritic Cell Migration in Skin Immunity
Baek, J.-H., Birchmeier, C., Zenke, M., & Hieronymus, T. (2012) · Journal of Immunology · doi:10.4049/jimmunol.1200729 · Cited by 91
Active Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis
Schoenfeld, J. D., Jinushi, M., Nakazaki, Y., Wiener, D. C., Park, J., Soiffer, R. J., Neuberg, D. S., Mihm, M. C., Hodi, F. S., & Dranoff, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1852 · Cited by 82
Tumor angiogenesis factors reduce leukocyte adhesion in vivo
Tromp, S. C., Egbrink, M. G. A. O., Dings, R. P. M., van Velzen, S., Slaaf, D. W., Hillen, H. F. P., Tangelder, G. J., Reneman, R. S., & Griffioen, A. W. (2000) · International Immunology · doi:10.1093/intimm/12.5.671 · Cited by 81
Four, S. D., Maenhout, S. K., Niclou, S. P., Thielemans, K., Neyns, B., & Aerts, J. L. (2016) · PubMed · Cited by 80
Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature
Facciponte, J. G., Ugel, S., Sanctis, F. D., Li, C., Wang, L., Nair, G. P., Sehgal, S., Raj, A., Matthaiou, E. I., Coukos, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67382 · Cited by 78
Pittet, C. L., Newcombe, J., Prat, A., & Arbour, N. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-155 · Cited by 73
Hochster, H. S., Bendell, J. C., Cleary, J. M., Foster, P., Zhang, W., He, X., Hernandez, G., Iizuka, K., & Eckhardt, S. G. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.673 · Cited by 71
Responsiveness of Stromal Fibroblasts to IFN-γ Blocks Tumor Growth via Angiostasis
Yu, L., Yang, W. C., Qin, C., Zhang, L., Deng, J., Liu, S., & Qin, Z. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901073 · Cited by 71
Wu, X., Li, J., Connolly, E. M., Liao, X., Ouyang, J., Giobbie‐Hurder, A., Lawrence, D. P., McDermott, D. F., Murphy, G. F., Zhou, J. M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0385 · Cited by 71
McDermott, D. F., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B. J., Fong, L. H., Joseph, R. W., Pal, S. K., Sznol, M., Hainsworth, J. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.431 · Cited by 70
Shi, S., Wang, R., Chen, Y., Song, H., Chen, L., & Huang, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065757 · Cited by 69
Lin, Y., Liang, Y., & Chiang, B. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0307164 · Cited by 67
Strauss, L., Volland, D., Kunkel, M., et al. (2005) · PubMed · Cited by 67
Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors
Hellwig, S. M. M., Damen, C. A., van Adrichem, N. P. H., Blijham, G. H., Groenewegen, G., & Griffioen, A. W. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)00310-8 · Cited by 65
Zhao, Y., Ting, K. K., Li, J., Cogger, V. C., Chen, J., Johansson, A., Ngiow, S. F., Holst, J., Grau, G. E., Goel, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3129 · Cited by 63
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.
Pogue-Geile, K., Yothers, G., Taniyama, Y., Tanaka, N., Gavin, P., Colangelo, L., Blackmon, N., Lipchik, C., Kim, S. R., Sharif, S., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt140 · Cited by 61
A Novel Function for Programmed Death Ligand-1
Jin, Y., Chauhan, S. K., Annan, J. E., Sage, P. T., Sharpe, A. H., & Dana, R. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.027 · Cited by 59
Vaccination against the extra domain‐B of fibronectin as a novel tumor therapy
Huijbers, E. J. M., Ringvall, M., Femel, J., Kalamajski, S., Lukinius, A., Åbrink, M., Hellman, L., & Olsson, A. (2010) · The FASEB Journal · doi:10.1096/fj.10-163022 · Cited by 59
Wu, F. T. H., Man, S., Xu, P., Chow, A., Paez-Ribes, M., Lee, C. R., Pirie-Shepherd, S. R., Emmenegger, U., & Kerbel, R. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0888 · Cited by 58
Self-citationPDGF upregulates CLEC-2 to induce T regulatory cells
Agrawal, S., Ganguly, S., Hajian, P., Cao, J., & Agrawal, A. (2015) · Oncotarget · doi:10.18632/oncotarget.5765 · Cited by 58
Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy
Schmittnaegel, M., & Palma, M. D. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.10.002 · Cited by 58
Gordin, M., Tesio, M., Cohen, S., Gore, Y., Lantner, F., Leng, L., Bucala, R., & Shachar, I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902566 · Cited by 57
Heskamp, S., Boerman, O. C., Molkenboer‐Kuenen, J. D. M., Oyen, W. J. G., van der Graaf, W. T. A., & van Laarhoven, H. W. M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28046 · Cited by 56
VEGF Requires the Receptor NRP-1 To Inhibit Lipopolysaccharide-Dependent Dendritic Cell Maturation
Oussa, N. A. E., Dahmani, A., Gomis, M., Richaud, M., Andreev, E., Navab-Daneshmand, A.-R., Taillefer, J., Carli, C., Boulet, S., Sabbagh, L., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601116 · Cited by 52
Jaini, R., Rayman, P. A., Cohen, P. A., Finke, J. H., & Tuohy, V. K. (2013) · International Journal of Cancer · doi:10.1002/ijc.28488 · Cited by 49
Avella, D. M., Li, G., Schell, T. D., Liu, D., Zhang, S. S.-M., Lou, X., Berg, A. S., Kimchi, E. T., Tagaram, H. R. S., Yang, Q. X., et al. (2011) · Hepatology · doi:10.1002/hep.24652 · Cited by 48
Deng, J., Liu, X., Rong, L., Chen, N., Li, X., Yang, W. C., Lu, Y., Yan, X., Qin, C., Zhang, L., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4340 · Cited by 46
Ghosh, S., Paul, A., & Sen, E. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01254-12 · Cited by 46
Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection
Chen, C., Feng, X., Liao, H.-Y., Jin, W.-J., Zhang, J., Wang, Y., Gong, L., Liu, J.-J., Yuan, X., Zhao, B.-B., et al. (2014) · Scientific Reports · doi:10.1038/srep06359 · Cited by 44
Cheng, J., Ye, H., Liu, Z., Xu, C., Zhang, Z., Liu, Y., & Sun, Y. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24492 · Cited by 39
Wentink, M. Q., Hackeng, T. M., Tabruyn, S. P., Puijk, W. C., Schwamborn, K., Altschuh, D., Meloen, R. H., Schuurman, T., Griffioen, A. W., & Timmerman, P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610258113 · Cited by 38
Vaccination approach to anti-angiogenic treatment of cancer
Wentink, M. Q., Huijbers, E. J. M., de Gruijl, T. D., Verheul, H. M. W., Olsson, A., & Griffioen, A. W. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.005 · Cited by 34
The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity
Benkhoucha, M., Molnarfi, N., Schneiter, G., Walker, P. R., & Lalive, P. H. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-154 · Cited by 33
Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia
Lee, J. Y., Park, S., Min, W.-S., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.027 · Cited by 26
Grenga, I., Kwilas, A. R., Donahue, R. N., Farsaci, B., & Hodge, J. W. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0096-7 · Cited by 26
Robo4 vaccines induce antibodies that retard tumor growth
Zhuang, X. A., Ahmed, F., Zhang, Y., et al. (2014) · Angiogenesis · doi:10.1007/s10456-014-9448-z · Cited by 23
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Metadata
- Authors
- Khan, K. A., & Kerbel, R. S.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2018-02-13
- Volume
- 15
- Issue
- 5
- Pages
- 310-324
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2794419219
- Cited by
- 657
- References
- 168
- FWCI
- 7.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.